Abstract:Abstract: Non-alcoholic fatty liver disease (NAFLD) is currently the utmost common chronic liver disorder that happens through all age groups and is identified to occur in 14%-30% of the general population, demonstrating a critical and grossing clinical issue because of the growing incidence of obesity and overweight. From the histological aspect, it looks like alcoholic liver damage, but it happens in patients who avoid remarkable alcohol usage. NAFLD comprises a broad spectrum, ranging from benign hepatocellular steatosis to inflammatory nonalcoholic steatohepatitis (NASH), different levels of fibrosis, and cirrhosis. Patients with NASH are more susceptible to more rapid progression to cirrhosis and hepatocellular carcinoma. There is no single factor that drives proceeding from simple steatosis to NASH. However, a combination of multi parameters such as genetic background, gut microflora, intake of high fat/ fructose dietary contents or methionine/choline-deficient diet, and consequently accumulated hepatocellular lipids mainly including triglycerides and also other bio-analytes, such as free fatty acids, cholesterol, and phospholipids display a crucial role in disease promotion. NAFLD is related to overweight and insulin resistance (IR) and is regarded as the hepatic presentation of the metabolic syndrome, an amalgamation of medical statuses such as hyperlipidemia, hypertension, type 2 diabetes, and visceral obesity. Despite the increasing prevalence of this disease, which imposes a remarkable clinical burden, most affected patients remain undiagnosed in a timely manner, largely related to the asymptomatic entity of NAFLD patients and the unavailability of accurate and efficient noninvasive diagnostic tests. However, liver biopsy is considered a gold standard for NAFLD diagnosis, but due to being expensive and invasiveness is inappropriate for periodic disease screening. Some noninvasive monitoring approaches have been established recently for NAFLD assessment. In addition to the problem of correct disease course prediction, no effective therapeutic modalities are approved for disease treatment. Imaging techniques can commonly validate the screening and discrimination of NAFLD; nevertheless, staging the disease needs a liver biopsy. The present therapeutic approaches depend on weight loss, sports activities, and dietary modifications, although different insulin-sensitizing drugs, antioxidants, and therapeutic agents seem hopeful. This review aims to focus on the current knowledge concerning epidemiology, pathogenesis, and different biochemical experiments and imaging modalities applied to diagnose the different grades of NAFLD and its management, as well as new data about pharmacological therapies for this disorder.

Non-Alcoholic Fatty Liver Disease and Metabolic Syndrome: Diagnostic and Laboratory Approach

[Research Advances in Diagnosis of Non-Alcoholic Fatty Liver Disease].

Non-alcoholic Fatty Liver Disease: an Early Mediator Predicting Metabolic Syndrome in Obese Children?

Relationship Between Nonalcoholic Fatty Liver Disease and Metabolic Syndrome.

Non-invasive testing in metabolic dysfunction-associated steatotic liver disease

Non-invasive Scores and Serum Biomarkers for Fatty Liver in the Era of Metabolic Dysfunction-associated Steatotic Liver Disease (MASLD): A Comprehensive Review From NAFLD to MAFLD and MASLD

Non-invasive diagnosis and staging of non-alcoholic fatty liver disease

The Epidemiology, Risk Profiling and Diagnostic Challenges of Nonalcoholic Fatty Liver Disease

Metabolomics and lipidomics in NAFLD: biomarkers and non-invasive diagnostic tests

Advancements in Diagnostic and Therapeutic Interventions of Non-alcoholic Fatty Liver Disease: A Literature Review

Noninvasive diagnosis and monitoring of nonalcoholic steatohepatitis: Present and future

Diagnostic modalities for nonalcoholic fatty liver disease, nonalcoholic steatohepatitis, and associated fibrosis

CLINICAL PROFILE WITH NON-ALCOHOLIC FATTY LIVER DISEASE AND METABOLIC SYNDROME PATIENTS

Progress in Serum Markers for Non-Alcoholic Fatty Liver Disease

Recent progresses on pathophysiology, diagnosis, therapeutic modalities, and management of Non-alcoholic fatty liver disorder

MAFLD in adults: non-invasive tests for diagnosis and monitoring of MAFLD

Identification of High-Risk Patients With Nonalcoholic Fatty Liver Disease in Endocrinology Clinics

A Comprehensive Review on Non-Alcoholic Fatty Liver Disease

Metabolic Derangement in Non-Alcoholic Fatty Liver Disease: Opportunities for Early Diagnostic and Prognostic Markers

A STUDY OF NON ALCOHOLIC FATTY LIVER DISEASE PATIENTS WITH METABOLIC SYNDROME

Portal Hypertension in Non-alcoholic Fatty Liver Disease in the Era of Non-invasive Assessment